Dr. Scott Gottlieb is a Special Partner on the NEA healthcare investment team; he was Venture Partner at NEA from in 2007 to 2017 until being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
In addition to his role as an investor, Dr. Gottlieb is a physician, policy expert, and advocate for healthcare entrepreneurship, innovation, and access. Dr. Gottlieb is an elected member of the National Academy of Medicine and currently a Resident Fellow at the American Enterprise Institute (AEI) in Washington, DC. In addition to his recent role as FDA Commissioner, Dr. Gottlieb previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. Earlier in his career, he worked as a healthcare analyst for the investment bank Alex. Brown & Sons. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.
In 2018 and again in 2019 Dr. Gottlieb was recognized by Fortune as one of \
|05/26/2022||1,232||Award at $0 per share.||0|
|05/26/2021||881||Award at $0 per share.||0|
|05/27/2020||963||Award at $0 per share.||0|
|02/04/2020||395||Award at $0 per share.||0|